Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 5/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11269746 | 0.87 | HPGDS (0.61) | PDE4DSMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10921097 | 0.86 | ALDH1A1 (0.49) | PDE4DSMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25211948 | 0.86 | ALDH1A1 (0.55) | PDE4DSMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL10920620 | 0.86 | ALDH1A1 (0.49) | PDE4DSMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5173650 | 0.83 | PDE4D (0.55) | PDE4DSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL2200905 | 0.82 | CDK5 (0.46) | SMN1; SMN2ALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL27967308 | 0.82 | MAPK1 (0.43) | CDC7MAPK1 | |
| SCHEMBL7460449 | 0.81 | PDE4D (0.52) | PDE4DSMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL14841145 | 0.80 | MAPK1 (0.43) | CDC7MAPK1 | |
| SCHEMBL17129029 | 0.78 | DUSP3 (0.48) | SMN1; SMN2ALDH1A1HPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-01 | — | — | US | disclosed |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
| EP-2763979-B1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-04 | — | — | US | disclosed |
| EP-2763979-A1 | 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| WO-2013054822-A1 | 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-18 | — | — | WO | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | PDE4D 1481/4885SMN1; SMN2 11/4885ALDH1A1 300/4885 |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | PDE4D 814/4885SMN1; SMN2 4368/4885ALDH1A1 1476/4885 |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | PDE4D 1481/4885SMN1; SMN2 11/4885ALDH1A1 300/4885 |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | PDE4D 1481/4885SMN1; SMN2 11/4885ALDH1A1 300/4885 |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | PDE4D 930/4885SMN1; SMN2 6/4885ALDH1A1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.